Novel SYN1 Variant in Two Brothers with Focal Epilepsy and Their Prompt Response to Valproate

Neuropediatrics. 2023 Jun;54(3):206-210. doi: 10.1055/a-2019-0136. Epub 2023 Jan 24.

Abstract

Synapsins are neuron-specific phosphoproteins that modulate neurotransmitter release, synaptic plasticity, and molecular processes shaping higher brain functions. Pathogenic synapsin-1 (SYN1) variants are associated with epilepsy, intellectual disabilities, and behavioral problems. We detected a novel SYN1 variant [c.477_479delTGG (p.Gly160del)] in brothers with focal epilepsy with secondary generalization. The deleted amino acid was found to be highly conserved among mammalian species. In electroencephalography, the older brother showed a bioelectrical status epilepticus and was also diagnosed with attention deficit hyperactivity disorder. Behavioral abnormalities were seen before or after the seizures. Both patients responded quickly to treatment with valproate. Our case reports are consistent with the clinical heterogeneity of the pathogenic SYN1 variants described in the literature.

Publication types

  • Case Reports

MeSH terms

  • Epilepsies, Partial* / drug therapy
  • Epilepsies, Partial* / genetics
  • Epilepsy*
  • Humans
  • Male
  • Mammals / metabolism
  • Siblings
  • Synapsins / chemistry
  • Synapsins / metabolism
  • Valproic Acid / therapeutic use

Substances

  • Synapsins
  • Valproic Acid